Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Researchers identify enzyme that controls spread of breast cancer

Researchers at the University of California, San Diego School of Medicine have identified an enzyme that controls the spread of breast cancer. The findings, reported in the current issue of PNAS, offer hope for the leading cause of breast cancer mortality worldwide.

2 Sep 2014

Many people with severe rheumatoid arthritis failing to take expensive medication

Large numbers of people with severe rheumatoid arthritis are failing to take expensive medication as prescribed, according to a new multi-centre study led by researchers in Manchester.

From The University of Manchester 28 Aug 2014

Microtechnologies to tackle problems of mobility industry and life sciences

CIC microGUNE, the Co-operative Research Centre into Microtechnologies, is coordinating the microSCALE project which seeks to generate innovative solutions based on microtechnologies to tackle the problems of the mobility industry and life sciences, among others.

28 Aug 2014

New biomarker may improve diagnosis of early-stage rheumatoid arthritis

A novel biomarker for rheumatoid arthritis (RA) has significant potential to help physicians better identify early-stage disease, when treatment can often arrest further disease progression and disability, according to a new study in The Journal of Rheumatology.

From Quest Diagnostics 28 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Highlights from the August issue of Mayo Clinic Health Letter

Here are highlights from the August issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required.

22 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

AMGF participates in collaborative effort to find best practices in managing RA patients

The American Medical Group Foundation today announced participants in a collaborative dedicated to finding best practices in managing patients with rheumatoid arthritis (RA).

19 Aug 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable."

12 Aug 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

11 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Rheumatoid arthritis is a condition that causes painful inflammation of several joints in the body. The joint capsule becomes swollen, and the disease can also destroy cartilage and bone as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world's population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease.

7 Aug 2014

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.

5 Aug 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

There is no cure for Alzheimer's disease and other forms of dementia, but the research community is one step closer to finding treatment.

29 Jul 2014

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Researchers identify enzyme that controls spread of breast cancer

Many people with severe rheumatoid arthritis failing to take expensive medication

Microtechnologies to tackle problems of mobility industry and life sciences

New biomarker may improve diagnosis of early-stage rheumatoid arthritis

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

Highlights from the August issue of Mayo Clinic Health Letter

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

AMGF participates in collaborative effort to find best practices in managing RA patients

Research findings call for clinical testing of relevant drugs to prevent NASH

Research shows new drug candidate can stop tumor growth in animal models

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Drug used for treating rheumatoid arthritis can improve health of kidney transplant recipients

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in